Tech Company Financing Transactions
Convergen Funding Round
Convergen closed a $15 million Seed funding round on 8/31/2026. Investors included Matrix Partners, BioTrack Capital and LAV Fund.
Transaction Overview
Company Name
Announced On
8/31/2026
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to further advance its proprietary degrader platform and accelerate its pipeline for neurodegenerative disorders and other protein aggregation diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Suzhou, Undisclosed
China
Suzhou, Undisclosed
China
Phone
Undisclosed
Email Address
Not Recorded
Overview
Convergen is a biotech company pioneering TrimTAC--next-generation bifunctional degraders that leverage TRIM21 to selectively clear pathological multimeric proteins. Founded to address unmet medical needs in neurodegenerative disease and beyond, the company combines cutting-edge academic research with industry-proven drug development expertise to advance therapies for significantly unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Co-Founder
Ting Han
Co-Founder
Jinquan Sun
Browse more venture capital transactions:
Prev: 8/28/2026: InstaAstro venture capital transaction
Next: 8/31/2026: Polymarket venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document all VC transactions involving tech companies. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs